OMARINI, Claudia
 Distribuzione geografica
Continente #
NA - Nord America 4.959
EU - Europa 3.637
AS - Asia 1.030
SA - Sud America 25
AF - Africa 24
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 10
Totale 9.703
Nazione #
US - Stati Uniti d'America 4.922
IT - Italia 1.031
IE - Irlanda 834
GB - Regno Unito 652
SE - Svezia 320
CN - Cina 302
DE - Germania 292
HK - Hong Kong 224
SG - Singapore 116
FR - Francia 114
UA - Ucraina 88
FI - Finlandia 75
TR - Turchia 64
IN - India 63
BG - Bulgaria 59
ID - Indonesia 56
VN - Vietnam 48
TW - Taiwan 33
CA - Canada 32
JP - Giappone 32
LT - Lituania 31
IQ - Iraq 28
BE - Belgio 23
MY - Malesia 22
CZ - Repubblica Ceca 21
EG - Egitto 21
AU - Australia 16
ES - Italia 13
RO - Romania 12
RU - Federazione Russa 12
EU - Europa 10
NL - Olanda 10
PL - Polonia 10
BR - Brasile 9
CH - Svizzera 9
CL - Cile 8
IR - Iran 8
KR - Corea 8
PK - Pakistan 8
PH - Filippine 7
MT - Malta 5
AR - Argentina 4
CR - Costa Rica 4
GR - Grecia 3
IL - Israele 3
IS - Islanda 3
NO - Norvegia 3
PT - Portogallo 3
DK - Danimarca 2
HR - Croazia 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
SY - Repubblica araba siriana 2
AL - Albania 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
CO - Colombia 1
EC - Ecuador 1
ET - Etiopia 1
HU - Ungheria 1
LV - Lettonia 1
MC - Monaco 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
NG - Nigeria 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
VE - Venezuela 1
ZM - Zambia 1
Totale 9.703
Città #
Dublin 830
Fairfield 642
Chandler 607
Ashburn 467
Southend 422
Woodbridge 300
Houston 283
Nyköping 261
Seattle 253
Wilmington 237
Ann Arbor 229
Dearborn 219
Hong Kong 217
Cambridge 181
Jacksonville 143
Modena 108
New York 105
Beijing 98
San Diego 76
Singapore 75
Milan 66
Helsinki 62
Princeton 62
Fremont 59
Sofia 59
Shanghai 56
Jakarta 53
Redwood City 53
Eugene 45
Rome 45
Dong Ket 43
Bologna 38
Izmir 37
Bremen 34
Enfield 32
Falls Church 31
San Giuliano Milanese 27
London 25
Parma 22
Asyut 21
Baghdad 21
Guangzhou 20
Brussels 18
Tokyo 17
Phoenix 16
Brno 15
Banqiao 14
Paris 14
Absecon 13
Boardman 13
Munich 13
Nanjing 12
Norwalk 12
Los Angeles 11
New Taipei 11
Ottawa 11
Padova 11
Des Moines 10
Frankfurt am Main 10
Reggio Emilia 10
Bergamo 9
Kunming 9
Sassuolo 9
Toronto 9
Caprarola 8
Castelvetrano 8
Napoli 8
Palermo 8
Turin 8
Chicago 7
Genoa 7
San Mateo 7
Santorso 7
Venezia 7
Amsterdam 6
Cardiff 6
Carpi 6
Istanbul 6
Madrid 6
Monza 6
Mumbai 6
Piacenza 6
San Marco 6
Sydney 6
Taranto 6
Vernon 6
Angera 5
Angers 5
Bangalore 5
Bari 5
Bomporto 5
Cagliari 5
Changchun 5
Chiswick 5
Falkenstein 5
Hefei 5
Longiano 5
Lugano 5
Marseille 5
Maruggio 5
Totale 7.148
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 370
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 264
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 245
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 242
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. 232
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 216
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 215
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 214
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 201
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 198
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 194
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 193
Immune characterization of breast cancer metastases: prognostic implications. 192
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 189
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 188
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 186
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 182
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 181
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 181
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 178
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 175
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 174
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 172
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 164
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 159
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 150
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 148
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 147
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 146
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 145
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 144
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 143
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 142
Lapatinib and renal impairment: a case report 139
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 137
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 135
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 134
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 134
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 126
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 124
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 124
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 124
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 122
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 122
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 121
The Role of Exosomes in Breast Cancer Diagnosis. 116
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 112
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 111
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 111
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 108
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 105
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 105
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 104
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 101
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 100
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 97
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 93
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 89
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 88
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 81
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. 65
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 50
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 50
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 47
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 44
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 36
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 27
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 24
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 23
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 20
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 20
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 19
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 18
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 18
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 16
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 12
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 7
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 6
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 3
Totale 9.838
Categoria #
all - tutte 39.577
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.577


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.506 107 74 49 122 158 248 267 132 142 76 81 50
2020/20211.615 153 102 78 126 188 129 70 182 103 197 125 162
2021/20221.393 77 148 117 59 53 115 65 72 134 129 254 170
2022/20232.688 195 271 152 189 175 205 47 157 976 50 169 102
2023/20241.439 75 66 103 139 175 130 162 212 54 64 104 155
2024/202591 91 0 0 0 0 0 0 0 0 0 0 0
Totale 9.838